JP2024523559A5 - - Google Patents
Info
- Publication number
- JP2024523559A5 JP2024523559A5 JP2023579554A JP2023579554A JP2024523559A5 JP 2024523559 A5 JP2024523559 A5 JP 2024523559A5 JP 2023579554 A JP2023579554 A JP 2023579554A JP 2023579554 A JP2023579554 A JP 2023579554A JP 2024523559 A5 JP2024523559 A5 JP 2024523559A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- human
- pharmaceutical product
- approximately
- product according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163214521P | 2021-06-24 | 2021-06-24 | |
| US63/214,521 | 2021-06-24 | ||
| US202163290364P | 2021-12-16 | 2021-12-16 | |
| US63/290,364 | 2021-12-16 | ||
| PCT/US2022/073148 WO2022272300A1 (en) | 2021-06-24 | 2022-06-24 | Methods of using aldosterone synthase inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024523559A JP2024523559A (ja) | 2024-06-28 |
| JP2024523559A5 true JP2024523559A5 (https=) | 2025-06-23 |
Family
ID=84545863
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023579554A Pending JP2024523559A (ja) | 2021-06-24 | 2022-06-24 | アルドステロン合成酵素阻害剤を使用する方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240277698A1 (https=) |
| EP (1) | EP4358959A4 (https=) |
| JP (1) | JP2024523559A (https=) |
| KR (1) | KR20240035483A (https=) |
| AU (2) | AU2022299103B2 (https=) |
| BR (1) | BR112023027025A2 (https=) |
| CA (1) | CA3223211A1 (https=) |
| IL (1) | IL309428A (https=) |
| MX (1) | MX2023015121A (https=) |
| WO (1) | WO2022272300A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2024310688A1 (en) * | 2023-06-29 | 2026-01-29 | AstraZeneca Ireland Limited | Crystal form of baxdrostat, and preparation method therefor and use thereof |
| CN121712504A (zh) * | 2023-07-27 | 2026-03-20 | 矿物疗法公司 | 用洛伦司他及两种或更多种降压药的组合治疗高血压的方法 |
| TW202525278A (zh) * | 2023-12-15 | 2025-07-01 | 愛爾蘭商阿斯特捷利康愛爾蘭有限公司 | 治療慢性腎病及高血壓之方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4777896A (en) * | 1995-02-10 | 1996-08-27 | G.D. Searle & Co. | Use of low dose amount of spironolactone for treatment of cardiovascular disease |
| US20070196510A1 (en) * | 2006-02-17 | 2007-08-23 | Gerber Michael J | Method for treating resistant hypertension |
| US9353081B2 (en) * | 2011-09-23 | 2016-05-31 | Hoffmann-La Roche Inc. | Bicyclic dihydroquinoline-2-one derivatives |
-
2022
- 2022-06-24 WO PCT/US2022/073148 patent/WO2022272300A1/en not_active Ceased
- 2022-06-24 MX MX2023015121A patent/MX2023015121A/es unknown
- 2022-06-24 BR BR112023027025A patent/BR112023027025A2/pt unknown
- 2022-06-24 JP JP2023579554A patent/JP2024523559A/ja active Pending
- 2022-06-24 CA CA3223211A patent/CA3223211A1/en active Pending
- 2022-06-24 AU AU2022299103A patent/AU2022299103B2/en active Active
- 2022-06-24 US US18/569,853 patent/US20240277698A1/en active Pending
- 2022-06-24 IL IL309428A patent/IL309428A/en unknown
- 2022-06-24 EP EP22829524.2A patent/EP4358959A4/en active Pending
- 2022-06-24 KR KR1020247002601A patent/KR20240035483A/ko active Pending
-
2026
- 2026-03-16 AU AU2026201954A patent/AU2026201954A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024523559A5 (https=) | ||
| JPH06102622B2 (ja) | 肥満の治療 | |
| JP2024540183A5 (https=) | ||
| JP2022536623A (ja) | 肺動脈性肺高血圧症の治療方法 | |
| JP2022533968A5 (https=) | ||
| KR20010015918A (ko) | 안면홍조를 감소시키기 위한 플루옥세틴 히드로클로라이드 | |
| US20040152625A1 (en) | Method for improving the pharmacokinetics of an NNRTI | |
| JP2004519424A5 (ja) | インシュリン分泌促進剤およびＨＭＧ−Ｃｏ−Ａレダクターゼ阻害剤およびＡＣＥ阻害剤から選択される活性成分を含む組み合わせ | |
| JP2024525164A5 (https=) | ||
| JP2000513356A (ja) | エナラプリルとロサルタンの組成物 | |
| JP2024539476A5 (https=) | ||
| JPH01261334A (ja) | アンギオテンシン転換酵素阻害剤を有効成分とした医療用調剤及びその製造方法 | |
| JP2023531930A5 (https=) | ||
| JP3837769B2 (ja) | 抗ウイルス剤 | |
| JP2008501023A (ja) | 小児患者での癌の治療 | |
| JP3885135B2 (ja) | Ｃ型又は非ｂ非ｃ型肝炎ウイルスによる肝機能異常の改善剤 | |
| JP2008535907A5 (https=) | ||
| SK284581B6 (sk) | Použitie levosimendanu alebo jeho farmaceuticky prijateľnej soli na výrobu liečiva na liečenie pľúcnej hypertenzie | |
| CZ20014685A3 (cs) | Lék pro léčbu nebo prevenci vazospazmu koronárního ątěpu | |
| JP4965791B2 (ja) | 敗血症性ショックの治療方法 | |
| CN113616651B (zh) | 一种复方降压药物组合物及其应用 | |
| Hart et al. | ACE inhibition versus calcium antagonism in the treatment of mild to moderate hypertension: a multicentre study. Ireland-Netherlands Lisinopril-Nifedipine Study Group | |
| JP2025511403A5 (https=) | ||
| KR20250155479A (ko) | 칸데사르탄, 암로디핀 및 인다파미드를 포함하는 고혈압 예방 또는 치료용 약제학적 복합제제 | |
| Man in’t Veld | The place of isradipine in the treatment of hypertension |